Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis

Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis

Abstract Background Current treatment guidelines for immune-mediated colitis (IMC) recommend 4 to 6 weeks of steroids as first-line therapy, followed by selective immunosuppressive therapy (SIT) (infliximab or vedolizumab) in patients who do not respond to steroids. We assessed the effect of early S...

Full description

Bibliographic Details
Main Authors: Hamzah Abu-Sbeih, Faisal S. Ali, Xuemei Wang, Niharika Mallepally, Ellie Chen, Mehmet Altan, Robert S. Bresalier, Aline Charabaty, Ramona Dadu, Amir Jazaeri, Bret Lashner, Yinghong Wang
Format: Article
Language:English
Published: BMJ Publishing Group 2019-04-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Colitis
Diarrhea
Immune checkpoint inhibitors
Immunotherapy
Infliximab
Vedolizumab
Online Access:http://link.springer.com/article/10.1186/s40425-019-0577-1

Internet

http://link.springer.com/article/10.1186/s40425-019-0577-1

Similar Items